メインコンテンツに移動
  • ELGAについて
    • ELGAについて
    • 超純水
    • 純水製造技術
    • 水中の不純物
    • ガイド&ホワイトペーパー
    • 認定パートナー
    • サステナビリティ
    • 臨床でのリスクの低減
    • 採用情報
    • イベント
    • 製薬におけるHPLC
    • HPLC用水の純度
  • ブログ
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment and sustainability
    • Life in the lab
    • Purelab product design
    • Science of the future
    • Water Purity
    • Water in the lab
  • お問い合わせ
  • English
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 中文
ホーム ELGA LabWater
  • 製品
  • 用途
  • ケーススタディ
  • サポート
  • 製品
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA全製品ライン
  • 用途
  • ケーススタディ
    • 超純水により南極の謎を解明
    • Ca’Foscari University- A New Method for Investigating Environmental Tracers in Ice
    • Ca’Foscari University- Investigating Contaminants in Antarctic Ice
    • DASA:ブラジル最大の医療診断企業
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® flex:現代的な研究手法における理想的なトレーニングシステム
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Siemens ADVIA分析装置用に市立総合病院がMEDICA®Proを導入
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • ジェネリック医薬品開発における超純水(I型水+)の重要性
    • 免疫血清学ラボの稼働時間最大化を支援するELGA
    • 南アジアのAbbott Diagnostics、ELGA MEDICAシステムを選択
  • サポート
    • サポート&サービス
    • ラボのプランニング
    • 製品を登録
    • Register Your Product (USA & Canada Only)
  • 製品
    • PURELAB
      • PURELAB Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB Chorus 2+
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® flex 1 & 2
      • PURELAB® flex 3 & 4
    • CENTRA
      • CENTRA® 60/120
      • CENTRA® RDS
      • CENTRA® R200
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® EDI 15/30
      • MEDICA® Pro EDI 60/120
      • MEDICA® Pro-LPS
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
    • BIOPURE
      • BIOPURE 7/15
      • BIOPURE 60/120
      • BIOPURE 200/300/600
    • ELGA全製品ライン
      • PURELAB® Classic
  • 用途
  • ケーススタディ
    • 超純水により南極の謎を解明
    • Ca’Foscari University- A New Method for Investigating Environmental Tracers in Ice
    • Ca’Foscari University- Investigating Contaminants in Antarctic Ice
    • DASA:ブラジル最大の医療診断企業
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® flex:現代的な研究手法における理想的なトレーニングシステム
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Siemens ADVIA分析装置用に市立総合病院がMEDICA®Proを導入
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • ジェネリック医薬品開発における超純水(I型水+)の重要性
    • 免疫血清学ラボの稼働時間最大化を支援するELGA
    • 南アジアのAbbott Diagnostics、ELGA MEDICAシステムを選択
  • サポート
    • サポート&サービス
    • ラボのプランニング
    • 製品を登録
    • Register Your Product (USA & Canada Only)
  • English
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 中文
  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • サイト管理者情報
  • ホーム
  • Node
  • A New Technique For Quantifying Bevacizumab In Eye Formulations
Clinical & Pharma
Science of the Future

A New Technique For Quantifying Bevacizumab In Eye Formulations

23 2月 2020
- by Dr Alison Halliday

Child eye test

Bevacizumab is a cancer drug that is also used ‘off-label’ to treat eye diseases. Researchers develop a rapid, sensitive and cost-effective new method for its routine analysis in ocular formulations.

Bevacizumab (Avastin®) is a monoclonal antibody that is approved for treating several types of cancer. By targeting the activity of vascular endothelial growth factor-A (VEGF-A) and blocking the growth of tumour blood vessels, this effectively cuts off the supply of oxygen and nutrients that fuel the tumour.

But ophthalmologists also use bevacizumab to treat chronic eye diseases caused by abnormal blood vessel growth in the retina at the back of the eye. These include the ‘wet’ type of age-related macular degeneration (AMD), which is a leading cause of blindness in older people. By injecting the antibody directly into the patient’s eyes, the aim is to block the growth of blood vessels and slow down sight loss. 

Although bevacizumab is not formally approved as an eye treatment, many consider it as an equally effective, yet cheaper alternative to a similar antibody called ranibizumab (Lucentis®) – which also targets VEGF-A and has been approved for this purpose.

Challenges Around Drug Delivery and Quality Control

A patient will need repeated doses of bevacizumab around every four to six weeks to maintain the drug at therapeutic levels in their eyes. But these injections are invasive and bring risks of potential complications. So scientists are aiming to develop sustained release systems – such as eye implants – that can enable longer-lasting delivery.

Another challenge is that biotherapeutic antibodies are not very stable – for example, they can aggregate, unfold or degrade, which can impact on their effectiveness. And so it is important that processes are in place that can facilitate the quality control of bevacizumab in eye formulations.

A Faster, Simpler and Cheaper Method

In a new study, researchers develop a new analytical method for use in in vitro studies of new eye implant delivery systems and in the routine quantification of bevacizumab in ophthalmic formulations.1 The scientists used size-exclusion chromatography (SEC) coupled with fluorescence detection. This is a powerful tool used for the preparation of biotherapeutics and represents a feasible alternative for other assays currently available for quantifying bevacizumab, which are both costly and time-consuming.

The researchers optimised their unique new chromatographic technique and then validated it for bevacizumab analysis, demonstrating that it is accurate, rapid and sensitive. The researchers made up the stock and standard solutions required for these experiments using an ELGA PURELAB® Flex laboratory water purification system.

This is the first study that couples SEC with fluorescence detector for the assay of bevacizumab. The results demonstrate that this method is cost-effective and suitable for the routine analysis of bevacizumab in pharmaceutical dosage forms –  and for measuring its levels in in vitro release studies of drug-loaded eye implants.

Why choose ELGA LabWater?

ELGA LabWater has been a trusted name in pure and ultrapure water since 1937. Our dedication to ultrapure and pure water is a guarantee that we will continue to provide the best solutions with the best service.

Reference:

  1. Jirgees, F. et al. A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations. Journal of Pharmaceutical and Biomedical Analysis 2019; 174: 145-150.

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

 

  • Enquiry
  • 見積もりを取得
  • デモを予約する
  • 承認されたパートナーを見つける

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

見積もりを取得

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

デモを予約する

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater本社

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

超純水スペシャリスト

  • サポート&サービス
  • イベント

ケーススタディ

  • Abbott Diagnostics(アボットダイアグノスティクス)
  • DASA Medical Diagnostics(DASA医療診断)
  • NeoDIN Medical Institute(NeoDIN医療機関)
  • UHNS(University Hospital of North Staffordshire NHS Trust/北スタンフォードシャア大学病院)
  • Olsberg Vocational College(オルスバーグ専門学校)

リソース

  • 超純水について
  • ガイド&ホワイトペーパー
  • 純水製造技術
  • 用途
  • 水中の不純物

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • 言語
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • 他のVeoliaサイト
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies

©VWS(UK)Ltd.はELGA LabWaterとして取引されています。2021-全著作権所有。
ELGAはVeoliaのグローバルなラボ用水のブランド名です。

  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • サイト管理者情報
Elga Veolia
TOP

© 2017 ELGA Veolia